Integer Holdings Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45826H1095
USD
70.62
0.74 (1.06%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Integer Holdings Corp. stock-summary
stock-summary
Integer Holdings Corp.
Pharmaceuticals & Biotechnology
Integer Holdings Corporation, formerly Greatbatch, Inc., is a medical device outsource manufacturing company. The Company's segments include Medical and Non-Medical. Medical segment includes Portable Medical, Cardio & Vascular, and Cardiac & Neuromodulation product lines. Non-Medical segment includes Electrochem product line. It serves the cardiac, neuromodulation and vascular markets. It also serves the non-medical power solutions market. In addition, the Company develops batteries for niche applications in energy, military, and environmental markets. Its brands include Greatbatch Medical, Lake Region Medical and Electrochem. Its primary customers include multi-national original equipment manufacturers (OEMs) and their affiliated subsidiaries.
Company Coordinates stock-summary
Company Details
5830 Granite Parkway., Suite 1150 , PLANO TX : 75024
stock-summary
Tel: 1 302 65875811 716 7595809
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 97 Schemes (61.44%)

Foreign Institutions

Held by 120 Foreign Institutions (11.37%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Bill Sanford
Independent Chairman of the Board
Mr. Joseph Dziedzic
President, Chief Executive Officer, Director
Ms. Pamela Bailey
Independent Director
Mr. James Hinrichs
Independent Director
Ms. Jean Hobby
Independent Director
Mr. Martin Maxwell
Independent Director
Mr. Filippo Passerini
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
473 Million
(Quarterly Results - Jun 2025)
Net Profit:
37 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,721 Million (Small Cap)

stock-summary
P/E

45.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.70

stock-summary
Return on Equity

5.31%

stock-summary
Price to Book

2.18